News & Updates

Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.

Higher consumption of plant-based food and a diet of egg, seafood, poultry, and meat appear to reduce the likelihood of depressive symptoms in adults, reports a China study.

The extended-release combination of naltrexone and bupropion (NB-ER) may be used as safe and effective treatment for weight reduction among individuals with overweight/obesity and mild to moderate symptoms of depression, suggests a study.

Management of metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve as clinicians refine the use of androgen deprivation therapy (ADT) and/or chemotherapy in combination with androgen receptor pathway inhibitors (ARPIs) in routine clinical practice. At an advisory board meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the University of Lübeck in Germany and Dr Darren Poon of the Hong Kong Sanatorium & Hospital discussed updated strategies and shared case studies to illustrate use of optimal ARPI-based regimens in patients with mHSPC.

Esketamine is more cost-effective than transcranial magnetic stimulation (rTMS) and electroconvul­sive therapy (ECT), but not when compared with other commonly used third-line treatments for treatment-resistant depression (TRD) in Hong Kong, a multi-armed modelling study has shown.